| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $29,769,658 | 4 | 100 |
Sells | $0 | 0 | 0 |
| George Gregory | 4 | $29.77M | 0 | $0 | $29.77M |
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal …
Over the last 12 months, insiders at Mesoblast Limited have bought $29.77M and sold $0 worth of Mesoblast Limited stock.
On average, over the past 5 years, insiders at Mesoblast Limited have bought $29.77M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: George Gregory () — $29.77M.
The last purchase of 2,324,072 shares for transaction amount of $3.44M was made by George Gregory () on 2026‑04‑10.
| 2026-04-10 | George Gregory | 2.32M 0.1837% | $1.48 | $3.44M | -0.47% | |||
| 2026-04-09 | George Gregory | 2.18M 0.6149% | $4.96 | $10.83M | +2.71% | |||
| 2026-04-09 | George Gregory | 1.48M 0.5576% | $6.63 | $9.82M | +2.71% | |||
| 2026-04-04 | George Gregory | 4M 0.298% | $1.42 | $5.68M | +0.10% |
| Increased Positions | 38 | +51.35% | 977,170 | +25.26% |
| Decreased Positions | 29 | -39.19% | 448,762 | -11.6% |
| New Positions | 13 | New | 340,997 | New |
| Sold Out Positions | 8 | Sold Out | 88,297 | Sold Out |
| Total Postitions | 83 | +12.16% | 4M | +13.66% |